Partnership between Oncomedics (CliniSciences Group) and Dexter com for distribution of the Oncogramme® in Romania
 |
 |
Oncomedics and Dexter com are pleased to announce their partnership for the distribution and promotion of the Oncogramme® (an in vitro diagnostic medical device developed by Oncomedics) in Romania. This partnership will make the Oncogramme® accessible to Romanian oncologists and their patients, thus contributing to Oncomedics' European development strategy.
All patients with metastatic colorectal cancer receive chemotherapy or a combination of chemotherapies, for which no prognostic tool exists, leading to a high failure rate (over 50% of patients) in the first line of treatment. The Oncogramme® addresses this problem by providing oncologists with a decision-making aid to identify the most effective treatment combinations for a patient with metastatic colorectal cancer. This is a functional assay in oncology designed to determine the sensitivity of a patient's tumor to one or more antitumor agents. The principle involves culturing patient's tumor cells and then placing them in the presence of standard of care treatments. The final response of these tumor cells to the antitumor agents is then analyzed. The first targeted indication is metastatic colon cancer, and the Oncogramme® will soon be extended to other cancers such as breast and ovarian cancer, in order to improve treatments by adapting them to each patient.
Viorel Mitrica, Managing Director at Dexter Com srl said : « We are grateful to Oncomedics company decided to invest trust in our company and offered us the right to distribute their solutions in Romania. Our hope is to contribute to the improvement of treatments for various cancers by introducing on the Romanian market the high performance innovative solutions offered by Oncomedics company. »
"We are delighted to be partnering with Dexter com, a major player in the distribution of research and diagnostic products in Romania, and to contribute to the improvement of treatments for various cancers thanks to the decision support for oncologists that Oncogramme® allows" comments Christophe Lautrette, President of Oncomedics.
About Oncomedics: Oncomedics is a biotechnology company specialising in the personalisation of cancer treatments. It develops in vitro diagnostic medical devices that provide practitioners (surgeons, pathologists and oncologists) with decision support in order to identify the most effective treatments for a patient. Oncomedics's mission is to enable patients to obtain personalised therapy through Oncogramme®. Founded in 2006 by Christophe Lautrette and Stéphanie Giraud, Oncomedics has its own laboratories and production units in Limoges (Nouvelle Aquitaine, France). After the approval by the « Haute Autorité de Santé », Oncomedics has obtained the derogatory reimbursement "Forfait Innovation" for its innovative diagnostic test Oncogramme® for a first indication, metastatic colorectal cancer. Oncomedics joined the CliniSciences Group in March 2022. Press contact: Daria Korejwo - Marketing Manager - info@Oncomedics.com
About Dexter com. Dexter Com is a distributor company for many world-renowned manufacturers of instrument and reagents for biomedical research. Established in 1996/1997 as a limited partnership of three associates: Lorand Savu, Nicusor Sarcan and Viorel.
Mitrica, the main business activity was set to be import and distribution in Romania of scientific instruments and supplies for biomedical research and related areas. Now, we have in our portfolio a full list of instruments, reagents and consumables for labs involved in molecular biology, cell biology, microbiology, biotechnology and clinical diagnostic. Our goal is to serve the research community in Romania with high technologically solutions of instruments and reagents. Our activity is driven by a high level of understanding of customer needs and demands and customer orientation. Our customer support was the key of our success in the past and we are confident that it will be in the future as well.